Gregory J. Flesher net worth and biography

Gregory Flesher Biography and Net Worth

Greg is the President and Chief Executive Officer of Reneo Pharmaceuticals and serves as a member of the company’s Board of Directors. Greg brings to Reneo more than 25 years of biopharmaceutical industry experience in executive management, corporate and business development, operations, sales and marketing, and clinical development. He has been closely involved with several novel development programs resulting in multiple product approvals and successful commercial launches in the U.S. and Europe.

Prior to joining Reneo, Greg was Chief Executive Officer and a member of the Board of Directors of Novus Therapeutics (Nasdaq: NVUS), a clinical-stage pharmaceutical company he took public in 2017 and led through the transformational acquisition of Anelixis Therapeutics in 2020. Prior to Novus, Greg was Chief Business Officer of publicly traded Avanir Pharmaceuticals (AVNR), a commercial-stage pharmaceutical company, where he led corporate and business development as well as corporate operations through the $3.5 billion acquisition of the company by Otsuka Pharmaceuticals in 2015. From 1995 to 2006, Greg held multiple leadership roles at Intermune (acquired by Roche), Amgen, and Eli Lilly and Company.

Greg received his B.S. in biology from Purdue University and studied biochemistry and molecular biology at Indiana University School of Medicine.

What is Gregory J. Flesher's net worth?: The estimated net worth of Gregory J. Flesher is at least $290,936.10 as of May 21st, 2019. Mr. Flesher owns 159,855 shares of Reneo Pharmaceuticals stock worth more than $290,936 as of December 22nd. This net worth estimate does not reflect any other assets that Mr. Flesher may own. Additionally, Mr. Flesher receives a salary of $569,700.00 as CEO at Reneo Pharmaceuticals. Learn More about Gregory J. Flesher's net worth.
How old is Gregory J. Flesher?: Mr. Flesher is currently 54 years old. There are 4 older executives and no younger executives at Reneo Pharmaceuticals. Learn More on Gregory J. Flesher's age.
What is Gregory J. Flesher's salary?: As the CEO of Reneo Pharmaceuticals, Inc., Mr. Flesher earns $569,700.00 per year. Learn More on Gregory J. Flesher's salary.
How do I contact Gregory J. Flesher?: The corporate mailing address for Mr. Flesher and other Reneo Pharmaceuticals executives is , , . Reneo Pharmaceuticals can also be reached via phone at 858-283-0280 and via email at [email protected]. Learn More on Gregory J. Flesher's contact information.
Has Gregory J. Flesher been buying or selling shares of Reneo Pharmaceuticals?: Gregory J. Flesher has not been actively trading shares of Reneo Pharmaceuticals during the last quarter. Most recently, on Wednesday, August 25th, Gregory J. Flesher bought 8,000 shares of Reneo Pharmaceuticals stock. The stock was acquired at an average cost of $8.00 per share, with a total value of $64,000.00. Learn More on Gregory J. Flesher's trading history.
Who are Reneo Pharmaceuticals' active insiders?: Reneo Pharmaceuticals' insider roster includes Michael Cruse (VP), Gregory Flesher (CEO), Vineet Jindal (CFO), and Bali Muralidhar (Director). Learn More on Reneo Pharmaceuticals' active insiders.
Are insiders buying or selling shares of Reneo Pharmaceuticals?: In the last twelve months, Reneo Pharmaceuticals insiders bought shares 4 times. They purchased a total of 670,520 shares worth more than $993,097.95. The most recent insider tranaction occured on September, 24th when Major Shareholder Braden Michael Leonard bought 29,600 shares worth more than $41,736.00. Insiders at Reneo Pharmaceuticals own 17.9% of the company. Learn More about insider trades at Reneo Pharmaceuticals.
Information on this page was last updated on 9/24/2024.

Gregory J. Flesher Insider Trading History at Reneo Pharmaceuticals

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
8/25/2021	Buy	8,000	$8.00	$64,000.00

Gregory J. Flesher Buying and Selling Activity at Reneo Pharmaceuticals

Reneo Pharmaceuticals Company Overview

Reneo Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the development and commercialization of therapies for patients with rare genetic mitochondrial diseases. The company's lead product candidate is REN001, a potent and selective agonist of the peroxisome proliferator-activated receptor delta that is in clinical development for genetic mitochondrial diseases comprising primary mitochondrial myopathies and long-chain fatty acid oxidation disorders. Reneo Pharmaceuticals, Inc. was incorporated in 2014 and is headquartered in Irvine, California.

Today's Range

Now: $1.82

$1.68

$1.90

50 Day Range

MA: $1.64

$1.31

$1.82

2 Week Range

Now: $1.82

$0.98

$9.21

Volume

437,500 shs

Average Volume

250,384 shs

Market Capitalization

$60.84 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.21

2025 could be “worse than the dot-com bust”, says man who predicted 2008 banking crisis

From Stansberry Research | Ad

Dan is sharing his latest work with the public. Because what he's tracking right now, he says, is too serious to keep private.

Click here to see Dan's full warning to the public.

Gregory Flesher Biography and Net Worth

What is Gregory J. Flesher's net worth?

How old is Gregory J. Flesher?

What is Gregory J. Flesher's salary?

How do I contact Gregory J. Flesher?

Has Gregory J. Flesher been buying or selling shares of Reneo Pharmaceuticals?

Who are Reneo Pharmaceuticals' active insiders?

Are insiders buying or selling shares of Reneo Pharmaceuticals?